TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02855307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patient's usual fast-acting insulin analog will be used.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patient's usual fast-acting insulin analog will be used.
Study: NCT01185288

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab in pre-filled syringes
Study: NCT01652768

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Research Questionnaires
Description: Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Research Questionnaires
Description: Hospital Anxiety and Depression Scale Pearlin \& Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
Study: NCT01185288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate capsule
Study: NCT03317236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: A fixed 50 mg exteded release formulation.
Study: NCT02855307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Patient's usual fast-acting insulin analog will be used.
Study: NCT04203407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACP game
Description: Participants in the intervention group will be divided into groups of 4 participants to play a 1-hour culturally-sensitive theory-driven ACP board game with 15-minute debriefing delivered by facilitators. The ACP board game is developed by the principle investigator in a previous project.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants in the control group will receive a 1-hour board game about health lifestyle.
Study: NCT05164549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injectable Product
Description: Investigational Medicinal Product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine Injectable Product
Description: Investigational Medicinal Product
Study: NCT02855307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop strategy
Description: Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
Study: NCT05164549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Standard of Care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Standard of Care
Study: NCT01492062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multiple Model Predictive Controller
Description: Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
Study: NCT01768728

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic left hemihepatectomy
Description: participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open left hemihepatectomy
Description: participants will be performed with traditional open left hepatectomy using laparotomic instruments
Study: NCT04309409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg nivolumab fixed dose given as 60-minute iv infusion every 4 weeks for 12 doses over 1 year
Study: NCT03345316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FFI-1010
Description: Intravenous single dosing
Study: NCT00278512

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Transplant
Description: Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: Allogeneic Stem Cell Transplant will be performed after conditioning

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplant
Description: Allogeneic Stem Cell Transplant will be performed after conditioning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Causes prevention of the cell division

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Causes prevention of the cell division

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG (rabbit)
Description: A rabbit polyclonal antibody to lymphocyte

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Hematopoietic growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: Hematopoietic growth factor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1h
Description: Humanized monoclonal antibody against CD52 antigen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: inhibits DNA synthesis or repair

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: immune suppressive drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna is a drug used to protect the bladder from the effects of the chemotherapy drugs
Study: NCT00597636

Intervention type: BEHAVIORAL
Intervention: Questionaire, blood sample
Description: Provide 30ml blood for laboratory assays Complete Health Questionnaire

Intervention type: BEHAVIORAL
Intervention: Questionaire, Blood sample
Description: Provide 30ml blood for laboratory assays Complete Health Questionnaire
Study: NCT03570411

Intervention type: DIAGNOSTIC_TEST
Intervention: T-SPOT®.CMV Test
Description: The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).

Intervention type: DIAGNOSTIC_TEST
Intervention: T-SPOT®.CMV Test
Description: The T-SPOT.CMV test (Oxford Diagnostic Laboratories) measures the strength of T cell responses to CMV specific antigens. Using whole blood samples obtained through a standard blood collection tube, white blood cells (WBC's) are separated and purified. The cells are quantified and placed into specially designed plates where they are challenged with antigens specific to the disease under study. Disease-specific cells responding to these antigens will release immune messenger molecules, called cytokines. We then use chemistry to allow us to visualize those WBCs releasing cytokines (and hence those which react to the antigen), resulting in a spot on the bottom of the plate, corresponding to the footprint of an individual reacting WBC. Finally, we use an automated image analysis system to identify and count each of these spots to give a quantitative readout. That quantitative readout gives us the frequency of responsive disease-specific cells (Oxford Immunotec, 2017).
Study: NCT02855307

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop strategy
Description: Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-hormone closed-loop strategy
Description: Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
Study: NCT01291498

Intervention type: DEVICE
Group type: OTHER
Intervention: High Intensity Focused Ultrasound
Description: One or two HIFU sessions
Study: NCT03300791

Intervention type: OTHER
Intervention: Admitted
Description: Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
Study: NCT01787448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gel vehicle
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical gel vehicle
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium lauryl sulfate 0.1%
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sodium chloride solution 0.9% (saline)
Description: 0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
Study: NCT01738750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost Information Included
Study: NCT03469128

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive processing therapy
Description: Psychological treatment for patients suffering from PTSD and SUD symptoms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Sertraline for the treatment of post-traumatic stress and SU disorders

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Placebo Control
Study: NCT00324025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycograb

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Study: NCT01568034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 25 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 25 mg single-dose
Study: NCT04285450

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K
Description: 1mg
Study: NCT01568034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 25 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 25 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 50 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 50 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 50 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 50 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 100 mg single-dose
Study: NCT04285450

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose
Study: NCT04434807

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive hematoma evacuation
Description: Neurosurgery performed via burr hole or minicraniotomy and using the Aurora surgiscope and evacuator (Integra Lifesciences)
Study: NCT02116348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin (Nerve growth factor)
Description: Cerebrolysin will be given to the intervention group
Study: NCT01568034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 100 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 100 mg single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Description: BIA 9-1067 - 100 mg single-dose
Study: NCT04497792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10Mg Tab
Description: Patients from treatment group received empagliflozin 10 mg daily additionally to previously prescribed diabetes medication

Intervention type: DRUG
Group type: OTHER
Intervention: hypoglycemic therapy
Description: hypoglycemic therapy.
Study: NCT03351855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-CTLs
Description: 2 to 4 infusions, once a week, for 1x10\^5\~4x10\^6 CTLs/kg by IV each time
Study: NCT04769726

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: almonds
Description: almond intervention (20 g) before three major meals (60g per day) for 3 days in subacute phase, before OGTT in the acute phase ad for 3 months in chronic phase
Study: NCT00571961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir)
Description: 4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Buprenorphine will be obtained through prescription at the subject's drug treatment program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical evaluations/Blood draws
Description: Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
Study: NCT01568034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single-dose
Study: NCT01537302

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTO crossing in femoropopliteal arteries CONNECT II
Description: CTO crossing in femoropopliteal arteries using the Ocelot System
Study: NCT01218880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 7.5mg
Description: M2ES Dosage：7.5mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 15mg
Description: M2ES Dosage：15mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 30mg
Description: M2ES Dosage：30mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M2ES 45mg
Description: M2ES Dosage：45mg/m2
Study: NCT03891121

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Splint
Description: Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Occlusal Splint
Description: Occlusal splints are appliances that were usually applied to the upper jaw and covering all teeth and they are made of autopolymerizing acrylic resin. It is produced by using 2 mm thick hard acrylic between the maxilla and mandible as defined by the Okeson.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: We diluted 100-U freeze-dried BTX-A with 1.0 milliliters of sodium chloride, resulting in a dose of 1.0 U per 0.1 mL. We administered all skin injections by using a 1-inch 30-gauge needle. Patients were placed with the Frankfurt horizontal plane parallel to the floor.
Study: NCT03086330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
Study: NCT00335218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Climodien / Lafamme (BAY86-5027)
Description: 1 tablet daily (2 mg EV + 2 mg DNG)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet daily
Study: NCT01568034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single-dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Carbidopa
Description: Levodopa 100 mg Carbidopa 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa/Benzerazide
Description: Levodopa 100 mg Benzerazide 25 mg
Study: NCT01436370

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose \[60 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine
Description: Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® \[15 mcg x 3 strains\]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
Study: NCT02490046

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Mannose
Description: Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: D Mannose
Description: Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
Study: NCT04396197

Intervention type: OTHER
Intervention: Physiotherapy
Description: Daily physiotherapy to include respiratory care and rehabilitation based on the individual therapists clinical reasoning
Study: NCT04182100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101
Description: P1101 (ropeginterferon alfa-2b) will be administered subcutaneously every 2 weeks at the starting dose of 100 μg every two weeks (or 50 μg in patients under another cytoreductive therapy). The dose should be gradually increased by 50 μg every two weeks (in parallel, other cytoreductive therapy should be decreased gradually, as appropriate) until stabilization of the hematological parameters is achieved (hematocrit \<45%, platelets \<400 x 10\^9/L and leukocytes \<10 x 10\^9/L). The maximum recommended single dose is 500 μg injected every two weeks. The dose will be maintained at the highest level which can be tolerated and delivers best possible disease response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Description: Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phlebotomy
Description: Phlebotomy is performed aiming at a hematocrit \< 45%. When the hematocrit value is 45% or higher, phlebotomy is performed. The volume of phlebotomy per procedure should be 200 to 400 mL while monitoring the circulatory dynamics such as blood pressure and pulse. In the elderly and patients with cardiovascular disorders, a small volume (100-200 mL) should be considered to avoid rapid changes in hemodynamics.